Kenvue Inc. (NYSE:KVUE) Shares Sold by Gradient Investments LLC

Gradient Investments LLC trimmed its position in shares of Kenvue Inc. (NYSE:KVUE) by 13.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 598,526 shares of the company’s stock after selling 89,780 shares during the period. Gradient Investments LLC’s holdings in Kenvue were worth $12,779,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in KVUE. Grove Bank & Trust increased its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Riverview Trust Co purchased a new stake in shares of Kenvue during the 3rd quarter worth about $30,000. Ashton Thomas Securities LLC acquired a new stake in Kenvue during the 3rd quarter worth approximately $35,000. Fortitude Family Office LLC raised its holdings in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the period. Finally, Versant Capital Management Inc lifted its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KVUE has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, UBS Group reduced their price target on Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $23.08.

Kenvue Stock Performance

Kenvue stock opened at $20.79 on Friday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $39.85 billion, a P/E ratio of 37.79, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The stock has a 50 day moving average of $22.14 and a 200-day moving average of $21.75.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm’s revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.31 EPS. On average, analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.95%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.